- Home
- LYEL vs CATX Comparison
LYEL vs CATX Comparison
Compare LYEL & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- CATX
- Stock Information
- Founded
- LYEL 2018
- CATX 1983
- Country
- LYEL United States
- CATX United States
- Employees
- LYEL N/A
- CATX N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- LYEL Health Care
- CATX Health Care
- Exchange
- LYEL Nasdaq
- CATX Nasdaq
- Market Cap
- LYEL 207.7M
- CATX 183.2M
- IPO Year
- LYEL 2021
- CATX N/A
- Fundamental
- Price
- LYEL $0.48
- CATX $1.94
- Analyst Decision
- LYEL Sell
- CATX Strong Buy
- Analyst Count
- LYEL 2
- CATX 11
- Target Price
- LYEL $1.00
- CATX $15.30
- AVG Volume (30 Days)
- LYEL 828.6K
- CATX 548.7K
- Earning Date
- LYEL 03-11-2025
- CATX 03-26-2025
- Dividend Yield
- LYEL N/A
- CATX N/A
- EPS Growth
- LYEL N/A
- CATX N/A
- EPS
- LYEL N/A
- CATX N/A
- Revenue
- LYEL $61,000.00
- CATX $1,454,000.00
- Revenue This Year
- LYEL N/A
- CATX N/A
- Revenue Next Year
- LYEL N/A
- CATX $1.15
- P/E Ratio
- LYEL N/A
- CATX N/A
- Revenue Growth
- LYEL N/A
- CATX 1.40
- 52 Week Low
- LYEL $0.48
- CATX $1.91
- 52 Week High
- LYEL $3.15
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- LYEL 38.70
- CATX 27.24
- Support Level
- LYEL $0.53
- CATX $2.32
- Resistance Level
- LYEL $0.63
- CATX $2.62
- Average True Range (ATR)
- LYEL 0.07
- CATX 0.19
- MACD
- LYEL -0.01
- CATX -0.02
- Stochastic Oscillator
- LYEL 1.69
- CATX 4.18
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.